A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation
暂无分享,去创建一个
R. West | Robert West | C. Gale | Jianhua Wu | J. Cowan | M. Hall | A. Orlowski | J. C. Cowan | Chris P Gale | Chris P. Gale
[1] A. Hess,et al. Management. , 2020, Anesthesiology.
[2] Michael B. Gravenor,et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study , 2017, Circulation.
[3] Mircea Cinteza,et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial , 2017, The Lancet.
[4] V. Mok,et al. Age-specific trends of atrial fibrillation-related ischaemic stroke and transient ischaemic attack, anticoagulant use and risk factor profile in Chinese population: a 15-year study , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[5] C. Sindet-Pedersen,et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark , 2017, European heart journal.
[6] M. Fornage,et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.
[7] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[8] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[9] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[10] G. Lip,et al. Stroke prevention in atrial fibrillation , 2016, The Lancet.
[11] B. Gersh,et al. No Decline in the Risk of Stroke Following Incident Atrial Fibrillation Since 2000 in the Community: A Concerning Trend , 2016, Journal of the American Heart Association.
[12] T. Uejima,et al. Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation - Shinken Database Analysis. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[13] P. Rothwell,et al. Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[14] C. Martinez,et al. Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013 , 2015, Heart.
[15] C. Martinez,et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC , 2015, Thrombosis and Haemostasis.
[16] Sudha Seshadri,et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.
[17] G. Hankey,et al. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[18] Mårten Rosenqvist,et al. High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke , 2014, Stroke.
[19] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[20] C. Murray,et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.
[21] C. Gale,et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England , 2013, Heart.
[22] C. Herzog,et al. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992-2007). , 2013, JAMA internal medicine.
[23] T. Holt,et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. , 2012, The British journal of general practice : the journal of the Royal College of General Practitioners.
[24] 是恒 之宏,et al. ガイドライン解説 The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC) : Guidelines for the management of atrial fibrillation , 2011 .
[25] A. Camm,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.
[26] G. Lip,et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. , 2010, The American journal of medicine.
[27] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[28] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[29] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[30] KjellAsplund,et al. High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke , 2014 .
[31] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.